Apimeds Pharmaceuticals US, Inc.APUS
Price (close)
$7.25
Market cap
—
P/E
—
Revenue (TTM)
—
Net income
-$58.2M
Dividend yield
—
1-year total return
-59.4%
Net margin
—
Revenue growth
—
Debt / equity
—
What Apimeds Pharmaceuticals US, Inc. does.
Apimeds Merger Sub, Inc., a Delaware corporation (“ Merger Sub ”), MindWave Innovations Inc, a Delaware corporation (“ MindWave ”),
Lokahi Therapeutics, Inc., a Nevada corporation (“ Bio Sub ”), and Erik Emerson, solely in his capacity as representative
Corporation ”). As a result of the Merger, MindWave became a direct wholly owned subsidiary of the Company. At the Effective
Revenue and profit, by fiscal year.
| Fiscal year | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Net income | — | -$777,694 | -$1.4M | -$6.0M |
| Free cash flow | — | — | — | -$9.0M |
More on APUS.
- Apimeds Pharmaceuticals US, Inc. summary
- Apimeds Pharmaceuticals US, Inc. financial statements
- Apimeds Pharmaceuticals US, Inc. key metrics
- Apimeds Pharmaceuticals US, Inc. health scores and style box
- Apimeds Pharmaceuticals US, Inc. earnings
- Apimeds Pharmaceuticals US, Inc. dividends
- Apimeds Pharmaceuticals US, Inc. valuation
- Apimeds Pharmaceuticals US, Inc. ownership and insiders
- Apimeds Pharmaceuticals US, Inc. peers
Figures from Apimeds Pharmaceuticals US, Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.